156 related articles for article (PubMed ID: 35732498)
1. Incidental discovery of acute myeloid leukemia during liquid biopsy of a lung cancer patient.
Nkosi D; Miller CA; Jajosky AN; Oltvai ZN
Cold Spring Harb Mol Case Stud; 2022 Jun; 8(4):. PubMed ID: 35732498
[TBL] [Abstract][Full Text] [Related]
2. Liquid biopsy assay for lung carcinoma using centrifuged supernatants from fine-needle aspiration specimens.
Hannigan B; Ye W; Mehrotra M; Lam V; Bolivar A; Zalles S; Barkoh BA; Duose D; Hu PC; Broaddus R; Stewart J; Heymach J; Medeiros LJ; Wistuba I; Luthra R; Roy-Chowdhuri S
Ann Oncol; 2019 Jun; 30(6):963-969. PubMed ID: 30887015
[TBL] [Abstract][Full Text] [Related]
3. FNA smears as a potential source of DNA for targeted next-generation sequencing of lung adenocarcinomas.
Treece AL; Montgomery ND; Patel NM; Civalier CJ; Dodd LG; Gulley ML; Booker JK; Weck KE
Cancer Cytopathol; 2016 Jun; 124(6):406-14. PubMed ID: 26882436
[TBL] [Abstract][Full Text] [Related]
4. Limits and potential of targeted sequencing analysis of liquid biopsy in patients with lung and colon carcinoma.
Rachiglio AM; Esposito Abate R; Sacco A; Pasquale R; Fenizia F; Lambiase M; Morabito A; Montanino A; Rocco G; Romano C; Nappi A; Iaffaioli RV; Tatangelo F; Botti G; Ciardiello F; Maiello MR; De Luca A; Normanno N
Oncotarget; 2016 Oct; 7(41):66595-66605. PubMed ID: 27448974
[TBL] [Abstract][Full Text] [Related]
5. Liquid biopsy of fine-needle aspiration supernatant for lung cancer genotyping.
Guibert N; Tsukada H; Hwang DH; Chambers E; Cibas ES; Bale T; Supplee J; Ulrich B; Sholl LM; Paweletz CP; Oxnard GR
Lung Cancer; 2018 Aug; 122():72-75. PubMed ID: 30032849
[TBL] [Abstract][Full Text] [Related]
6. Centrifuged supernatants from FNA provide a liquid biopsy option for clinical next-generation sequencing of thyroid nodules.
Ye W; Hannigan B; Zalles S; Mehrotra M; Barkoh BA; Williams MD; Cabanillas ME; Edeiken-Monroe B; Hu P; Duose D; Wistuba II; Medeiros LJ; Stewart J; Luthra R; Roy-Chowdhuri S
Cancer Cytopathol; 2019 Mar; 127(3):146-160. PubMed ID: 30620446
[TBL] [Abstract][Full Text] [Related]
7. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
[TBL] [Abstract][Full Text] [Related]
8. Test Feasibility of Next-Generation Sequencing Assays in Clinical Mutation Detection of Small Biopsy and Fine Needle Aspiration Specimens.
Zheng G; Tsai H; Tseng LH; Illei P; Gocke CD; Eshleman JR; Netto G; Lin MT
Am J Clin Pathol; 2016 May; 145(5):696-702. PubMed ID: 27247373
[TBL] [Abstract][Full Text] [Related]
9. NGS Analysis of Liquid Biopsy (LB) and Formalin-Fixed Paraffin-Embedded (FFPE) Melanoma Samples Using Oncomine™ Pan-Cancer Cell-Free Assay.
Olbryt M; Rajczykowski M; Bal W; Fiszer-Kierzkowska A; Cortez AJ; Mazur M; Suwiński R; Widłak W
Genes (Basel); 2021 Jul; 12(7):. PubMed ID: 34356096
[TBL] [Abstract][Full Text] [Related]
10. Identification and monitoring of somatic mutations in circulating cell-free tumor DNA in lung cancer patients.
Francaviglia I; Magliacane G; Lazzari C; Grassini G; Brunetto E; Dal Cin E; Girlando S; Medicina D; Smart CE; Bulotta A; Gregorc V; Pecciarini L; Doglioni C; Cangi MG
Lung Cancer; 2019 Aug; 134():225-232. PubMed ID: 31319985
[TBL] [Abstract][Full Text] [Related]
11. Profiling of circulating tumor DNA in plasma of non-small cell lung cancer patients, monitoring of epidermal growth factor receptor p.T790M mutated allelic fraction using beads, emulsion, amplification, and magnetics companion assay and evaluation in future application in mimicking circulating tumor cells.
Garcia J; Wozny AS; Geiguer F; Delherme A; Barthelemy D; Merle P; Tissot C; Jones FS; Johnson C; Xing X; Xu Z; Edelstein DL; Brevet M; Souquet PJ; Rodriguez-Lafrasse C; Payen L; Couraud S
Cancer Med; 2019 Jul; 8(8):3685-3697. PubMed ID: 31112372
[TBL] [Abstract][Full Text] [Related]
12. Heterogeneous mutation pattern in tumor tissue and circulating tumor DNA warrants parallel NGS panel testing.
Guo Q; Wang J; Xiao J; Wang L; Hu X; Yu W; Song G; Lou J; Chen J
Mol Cancer; 2018 Aug; 17(1):131. PubMed ID: 30153823
[TBL] [Abstract][Full Text] [Related]
13. Targeted next-generation sequencing using fine-needle aspirates from adenocarcinomas of the lung.
Karnes HE; Duncavage EJ; Bernadt CT
Cancer Cytopathol; 2014 Feb; 122(2):104-13. PubMed ID: 24227699
[TBL] [Abstract][Full Text] [Related]
14. Clinical mutational profiling of bone metastases of lung and colon carcinoma and malignant melanoma using next-generation sequencing.
Zheng G; Lin MT; Lokhandwala PM; Beierl K; Netto GJ; Gocke CD; Eshleman JR; McCarthy E; Illei PB
Cancer Cytopathol; 2016 Oct; 124(10):744-753. PubMed ID: 27286239
[TBL] [Abstract][Full Text] [Related]
15. Using "residual" FNA rinse and body fluid specimens for next-generation sequencing: An institutional experience.
Wei S; Lieberman D; Morrissette JJ; Baloch ZW; Roth DB; McGrath C
Cancer Cytopathol; 2016 May; 124(5):324-9. PubMed ID: 26682952
[TBL] [Abstract][Full Text] [Related]
16. Next-generation sequencing for molecular diagnosis of lung adenocarcinoma specimens obtained by fine needle aspiration cytology.
Qiu T; Guo H; Zhao H; Wang L; Zhang Z
Sci Rep; 2015 Jun; 5():11317. PubMed ID: 26066407
[TBL] [Abstract][Full Text] [Related]
17. Cell-free circulating tumor DNA supplementing tissue biopsies for identification of targetable mutations: Implications for precision medicine and considerations for reconciling results.
Hicks JK; Saller J; Wang E; Boyle T; Gray JE
Lung Cancer; 2017 Sep; 111():135-138. PubMed ID: 28838384
[TBL] [Abstract][Full Text] [Related]
18. Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer.
Villaflor V; Won B; Nagy R; Banks K; Lanman RB; Talasaz A; Salgia R
Oncotarget; 2016 Oct; 7(41):66880-66891. PubMed ID: 27602770
[TBL] [Abstract][Full Text] [Related]
19. The diagnostic importance of pathogenic variants and variant coexistence determined by NGS-based liquid biopsy approach in patients with lung adenocarcinoma.
Cine N; Ali Sen E; Demir G; Gokbayrak M; Guzdolu E; Sertdemir N; Aydin D; Kurtas O; Reka S; Sunnetci-Akkoyunlu D; Eren-Keskin S; Uygun K; Cabuk D; Gorkem Aksu M; Zafer Canturk N; Savli H
Mol Cell Probes; 2022 Aug; 64():101819. PubMed ID: 35490794
[TBL] [Abstract][Full Text] [Related]
20. Clinical feasibility of NGS liquid biopsy analysis in NSCLC patients.
Papadopoulou E; Tsoulos N; Tsantikidi K; Metaxa-Mariatou V; Stamou PE; Kladi-Skandali A; Kapeni E; Tsaousis G; Pentheroudakis G; Petrakis D; Lampropoulou DI; Aravantinos G; Varthalitis I; Kesisis G; Boukovinas I; Papakotoulas P; Katirtzoglou N; Athanasiadis E; Stavridi F; Christodoulou C; Koumarianou A; Eralp Y; Nasioulas G
PLoS One; 2019; 14(12):e0226853. PubMed ID: 31860648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
